Skyworks Solutions
Web results:
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in a complex and evolving world. Learn more
Idexx Laboratories office IDEXX Laboratories, Inc. is an American multinational corporation [3] [4] engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
RealPCR testing Definitive answers, faster. IDEXX RealPCR testing helps you treat with precision and resolve infections quickly. Real-time PCR is a closed-tube system that delivers shorter assay run times, virtually eliminates false positives, and provides quantitative results that are both faster and more sensitive than conventional PCR.
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in a complex and evolving world. Find out more
An innovation leader in every industry we serve, IDEXX helps pet owners worldwide keep their companion animals healthy and happy, ensure safe drinking water for billions, and to help farmers protect livestock and poultry from disease.
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in a complex and evolving world. Find out more
Your learning platform uses cookies to optimize performance, preferences, usage & statistics. By accepting them, you consent to store on your device only the cookies that don't require consent.
Corporate Headquarters IDEXX Laboratories, Inc. One IDEXX Drive Westbrook, Maine 04092 United States. 1-800-548-6733 1-207-556-0300. IDEXX Ethics Hotline
Analyst Report: IDEXX Laboratories, Inc.Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product ...
IDEXX Laboratories Inc IDXX reported Q2 revenues of $861 million, an increase of 4% Y/Y on a reported basis and 6.5% on an organic basis, missing the consensus of $864.61 million.